US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VivoSim Lab, Inc.

2.02

+0.03001.51%

Post-market: 2.110.0900+4.46%16:40 EST

Volume:89.11K

Turnover:184.01K

Market Cap:5.25M

PE:-3.85

High:2.17

Open:1.95

Low:1.93

Close:1.99

52wk High:21.96

52wk Low:1.41

Shares:2.60M

Float Shares:2.57M

Volume Ratio:1.05

T/O Rate:3.46%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5253

EPS(LYR):-1.6999

ROE:-51.07%

ROA:-132.52%

PB:1.18

PE(LYR):-1.19

Loading ...

Overview Company News Filings

VivoSim Labs Unveils NAMkind Models Showing Strong Clinical Correlation for Antibody Drug Conjugate Toxicity

Top Premarket Gainers

MT Newswires Live

VivoSim Labs Signs Distribution Agreements with JCBio in Korea and Tekon Biotech in China for NAMKind Toxicology Services

Vivosim Expands Asia-Pacific Access to Namkind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

THOMSON REUTERS

BRIEF-Vivosim Labs Appoints Amar Sethi, M.D., Ph.D. As Chief Scientific Officer

VivoSim Labs Names Amar Sethi Chief Scientific Officer

Vivosim Labs Appoints Amar Sethi, M.d., Ph.d. as Chief Scientific Officer

THOMSON REUTERS

Press Release: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer

VivoSim Labs Inc. held annual shareholder meeting

VivoSim Labs Inc. Files Initial Statement of Beneficial Ownership for Chief Scientific Officer Amar Akhtar Sethi

VivoSim Labs Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Tony Serge Lialin

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/VIVS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VIVS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VIVS\",,,,,undefined,":{"symbol":"VIVS","market":"US","secType":"STK","nameCN":"VivoSim Lab, Inc.","latestPrice":2.02,"timestamp":1771621200000,"preClose":1.99,"halted":0,"volume":89110,"hourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.02,"latestTime":"16:40 EST","volume":1302,"amount":2756.140002,"timestamp":1771623640818,"change":0.09,"changeRate":0.044554,"amplitude":0.074257},"delay":0,"changeRate":0.015075376884422124,"floatShares":2572005,"shares":2599794,"eps":-0.525304,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"02-20 17:21:50 EST","open":1.95,"high":2.17,"low":1.93,"amount":184008.327181,"amplitude":0.120603,"askPrice":2.26,"askSize":391,"bidPrice":1.82,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.525304,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771635600000},"marketStatusCode":4,"adr":0,"listingDate":1373515200000,"exchange":"NASDAQ","adjPreClose":1.99,"preHourTrading":{"tag":"盘前","latestPrice":1.99,"preClose":1.99,"latestTime":"09:20 EST","volume":85,"amount":165.16799650000002,"timestamp":1771597212237,"change":0,"changeRate":0,"amplitude":0.040201},"postHourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.02,"latestTime":"16:40 EST","volume":1302,"amount":2756.140002,"timestamp":1771623640818,"change":0.09,"changeRate":0.044554,"amplitude":0.074257},"volumeRatio":1.04701},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VIVS\",,,,,undefined,":{"symbol":"VIVS","floatShares":2572005,"roa":"-132.52%","roe":"-51.07%","lyrEps":-1.699907,"volumeRatio":1.04701,"shares":2599794,"dividePrice":0,"high":2.17,"amplitude":0.120603,"preClose":1.99,"low":1.93,"week52Low":1.41,"pbRate":"1.18","psRate":"36.98","week52High":21.96,"institutionHeld":0,"latestPrice":2.02,"committee":-0.323181,"eps":-0.525304,"divideRate":0,"volume":89110,"delay":0,"ttmEps":-0.525304,"open":1.95,"prevYearClose":1.81,"prevWeekClose":2,"prevMonthClose":2.92,"prevQuarterClose":1.81,"fiveDayClose":1.91,"twentyDayClose":2,"sixtyDayClose":2.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VIVS\",params:#limit:5,,,undefined,":[{"date":"2026-02-11","symbol":"VIVS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770843600000,"name":null,"time":"Post Market","dateTimestamp":1770786000000,"actualEps":null},{"market":"US","date":"2025-11-06","symbol":"VIVS","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.98},{"market":"US","date":"2025-08-12","symbol":"VIVS","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-1.14},{"market":"US","date":"2025-06-05","symbol":"VIVS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1749096000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-03-21","symbol":"VIVS","defaultRemindTime":1742563800000,"type":"split","dateTimestamp":1742529600000,"forFactor":12,"toFactor":1,"ratio":12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VIVS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VIVS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VIVS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VIVS","date":"2026-02-19","current":-3.788283,"percent":0.050808,"low":-6.25416,"twenty":-2.740793,"median":-0.692832,"eighty":-0.452111,"high":-0.239025,"avg":-1.477848,"sd":1.291304,"marketCap":4981207},"quantilePoints":[{"date":"2024-05-31","current":-0.963147,"twenty":-0.792497,"median":-0.671162,"eighty":-0.661504,"marketCap":14130334},{"date":"2024-06-07","current":-0.940616,"twenty":-0.974746,"median":-0.940616,"eighty":-0.672676,"marketCap":13799784},{"date":"2024-06-14","current":-0.887326,"twenty":-0.967771,"median":-0.932486,"eighty":-0.803888,"marketCap":13017959},{"date":"2024-06-21","current":-0.791912,"twenty":-0.954135,"median":-0.915735,"eighty":-0.804294,"marketCap":11618147},{"date":"2024-06-28","current":-0.746557,"twenty":-0.940538,"median":-0.887326,"eighty":-0.743853,"marketCap":10952734},{"date":"2024-07-05","current":-0.737642,"twenty":-0.939205,"median":-0.822868,"eighty":-0.738524,"marketCap":10821950},{"date":"2024-07-12","current":-0.664172,"twenty":-0.933602,"median":-0.76174,"eighty":-0.706099,"marketCap":9744067},{"date":"2024-07-19","current":-0.578946,"twenty":-0.930565,"median":-0.746557,"eighty":-0.664172,"marketCap":8493722},{"date":"2024-07-26","current":-0.577379,"twenty":-0.924492,"median":-0.739847,"eighty":-0.617558,"marketCap":8470727},{"date":"2024-08-02","current":-0.535844,"twenty":-0.899473,"median":-0.734703,"eighty":-0.576281,"marketCap":7861363},{"date":"2024-08-09","current":-0.601951,"twenty":-0.891715,"median":-0.702866,"eighty":-0.577692,"marketCap":8419492},{"date":"2024-08-16","current":-0.621174,"twenty":-0.879352,"median":-0.664172,"eighty":-0.581087,"marketCap":8688362},{"date":"2024-08-23","current":-0.67969,"twenty":-0.842538,"median":-0.663883,"eighty":-0.589715,"marketCap":9506820},{"date":"2024-08-30","current":-0.637102,"twenty":-0.816677,"median":-0.663684,"eighty":-0.590571,"marketCap":8911141},{"date":"2024-09-06","current":-0.59536,"twenty":-0.791912,"median":-0.660499,"eighty":-0.592944,"marketCap":8327307},{"date":"2024-09-13","current":-0.59536,"twenty":-0.773888,"median":-0.655973,"eighty":-0.589978,"marketCap":8327307},{"date":"2024-09-20","current":-0.545271,"twenty":-0.749593,"median":-0.637102,"eighty":-0.577379,"marketCap":7626708},{"date":"2024-09-27","current":-0.511659,"twenty":-0.748369,"median":-0.626667,"eighty":-0.572293,"marketCap":7156568},{"date":"2024-10-04","current":-0.511878,"twenty":-0.746557,"median":-0.620625,"eighty":-0.568073,"marketCap":7159641},{"date":"2024-10-11","current":-0.491063,"twenty":-0.74401,"median":-0.615133,"eighty":-0.556415,"marketCap":6868502},{"date":"2024-10-18","current":-0.516331,"twenty":-0.742051,"median":-0.606345,"eighty":-0.545271,"marketCap":7221915},{"date":"2024-10-25","current":-0.485461,"twenty":-0.737642,"median":-0.603083,"eighty":-0.521764,"marketCap":6790137},{"date":"2024-11-01","current":-0.510838,"twenty":-0.734703,"median":-0.601951,"eighty":-0.513636,"marketCap":7145086},{"date":"2024-11-08","current":-0.492018,"twenty":-0.734703,"median":-0.59536,"eighty":-0.510508,"marketCap":6170895},{"date":"2024-11-15","current":-0.511988,"twenty":-0.709234,"median":-0.589978,"eighty":-0.505947,"marketCap":6421358},{"date":"2024-11-22","current":-0.490058,"twenty":-0.705315,"median":-0.581661,"eighty":-0.496886,"marketCap":6146310},{"date":"2024-11-29","current":-0.582557,"twenty":-0.701397,"median":-0.578162,"eighty":-0.496886,"marketCap":7306427},{"date":"2024-12-06","current":-0.562342,"twenty":-0.689309,"median":-0.577379,"eighty":-0.501808,"marketCap":7052891},{"date":"2024-12-13","current":-0.495694,"twenty":-0.681058,"median":-0.57573,"eighty":-0.499264,"marketCap":6216992},{"date":"2024-12-20","current":-0.441052,"twenty":-0.6791,"median":-0.572293,"eighty":-0.49526,"marketCap":5531679},{"date":"2024-12-27","current":-0.449628,"twenty":-0.678819,"median":-0.571195,"eighty":-0.490661,"marketCap":5639239},{"date":"2025-01-03","current":-0.556829,"twenty":-0.672907,"median":-0.568073,"eighty":-0.49046,"marketCap":6983745},{"date":"2025-01-10","current":-0.490181,"twenty":-0.664172,"median":-0.568073,"eighty":-0.490357,"marketCap":6147846},{"date":"2025-01-17","current":-0.474131,"twenty":-0.664074,"median":-0.562171,"eighty":-0.487102,"marketCap":5946555},{"date":"2025-01-24","current":-0.419,"twenty":-0.663684,"median":-0.558014,"eighty":-0.485461,"marketCap":5255095},{"date":"2025-01-31","current":-0.44289,"twenty":-0.663594,"median":-0.556415,"eighty":-0.474131,"marketCap":5554727},{"date":"2025-02-07","current":-0.428556,"twenty":-0.660499,"median":-0.551293,"eighty":-0.468872,"marketCap":5374948},{"date":"2025-02-14","current":-0.472906,"twenty":-0.659274,"median":-0.546415,"eighty":-0.461402,"marketCap":5931189},{"date":"2025-02-21","current":-0.520039,"twenty":-0.658549,"median":-0.542249,"eighty":-0.462764,"marketCap":6440682},{"date":"2025-02-28","current":-0.916058,"twenty":-0.663612,"median":-0.545843,"eighty":-0.465065,"marketCap":11345377},{"date":"2025-03-07","current":-0.742992,"twenty":-0.678775,"median":-0.54911,"eighty":-0.466535,"marketCap":9201960},{"date":"2025-03-14","current":-0.699132,"twenty":-0.681058,"median":-0.554946,"eighty":-0.468454,"marketCap":8658746},{"date":"2025-03-21","current":-0.452132,"twenty":-0.681058,"median":-0.553477,"eighty":-0.468454,"marketCap":5599653},{"date":"2025-03-28","current":-0.347018,"twenty":-0.6791,"median":-0.548844,"eighty":-0.460321,"marketCap":4297822},{"date":"2025-04-04","current":-0.305261,"twenty":-0.678775,"median":-0.545271,"eighty":-0.448893,"marketCap":3780657},{"date":"2025-04-11","current":-0.239745,"twenty":-0.676584,"median":-0.537699,"eighty":-0.442253,"marketCap":2969242},{"date":"2025-04-17","current":-0.247665,"twenty":-0.670012,"median":-0.532652,"eighty":-0.441052,"marketCap":3067325},{"date":"2025-04-25","current":-0.267823,"twenty":-0.664899,"median":-0.528415,"eighty":-0.439043,"marketCap":3316991},{"date":"2025-05-02","current":-0.287982,"twenty":-0.664172,"median":-0.524922,"eighty":-0.433701,"marketCap":3566658},{"date":"2025-05-09","current":-0.273583,"twenty":-0.663879,"median":-0.520039,"eighty":-0.428874,"marketCap":3388325},{"date":"2025-05-16","current":-0.298061,"twenty":-0.66363,"median":-0.518608,"eighty":-0.426522,"marketCap":3691491},{"date":"2025-05-23","current":-0.287982,"twenty":-0.663349,"median":-0.515786,"eighty":-0.420029,"marketCap":3566658},{"date":"2025-05-30","current":-0.268385,"twenty":-0.662111,"median":-0.513636,"eighty":-0.417726,"marketCap":3323946},{"date":"2025-06-06","current":-1.315277,"twenty":-0.662111,"median":-0.511933,"eighty":-0.415594,"marketCap":3272408},{"date":"2025-06-13","current":-1.807734,"twenty":-0.664172,"median":-0.514439,"eighty":-0.416647,"marketCap":4497643},{"date":"2025-06-20","current":-1.47346,"twenty":-0.678193,"median":-0.516331,"eighty":-0.416941,"marketCap":3665969},{"date":"2025-06-27","current":-1.483805,"twenty":-0.696612,"median":-0.519913,"eighty":-0.417628,"marketCap":3691707},{"date":"2025-07-03","current":-1.640545,"twenty":-0.705315,"median":-0.520902,"eighty":-0.41802,"marketCap":4081676},{"date":"2025-07-11","current":-2.058518,"twenty":-0.734703,"median":-0.526707,"eighty":-0.418755,"marketCap":5121594},{"date":"2025-07-18","current":-1.943576,"twenty":-0.742992,"median":-0.528748,"eighty":-0.419,"marketCap":4835616},{"date":"2025-07-25","current":-2.309302,"twenty":-0.749593,"median":-0.533991,"eighty":-0.420715,"marketCap":5745544},{"date":"2025-08-01","current":-1.954025,"twenty":-0.822868,"median":-0.540901,"eighty":-0.424268,"marketCap":4861614},{"date":"2025-08-08","current":-1.825498,"twenty":-0.887326,"median":-0.546415,"eighty":-0.424758,"marketCap":4541840},{"date":"2025-08-15","current":-2.355123,"twenty":-0.916058,"median":-0.551293,"eighty":-0.425125,"marketCap":4679629},{"date":"2025-08-22","current":-2.590635,"twenty":-0.94042,"median":-0.556415,"eighty":-0.427453,"marketCap":5147592},{"date":"2025-08-29","current":-2.446711,"twenty":-0.974805,"median":-0.558014,"eighty":-0.428556,"marketCap":4861614},{"date":"2025-09-05","current":-2.956987,"twenty":-1.221393,"median":-0.562171,"eighty":-0.428654,"marketCap":5875534},{"date":"2025-09-12","current":-4.834544,"twenty":-1.517243,"median":-0.568073,"eighty":-0.428776,"marketCap":9606238},{"date":"2025-09-19","current":-5.142018,"twenty":-1.544411,"median":-0.571195,"eighty":-0.428899,"marketCap":10217190},{"date":"2025-09-26","current":-4.513985,"twenty":-1.617556,"median":-0.57395,"eighty":-0.430211,"marketCap":8969289},{"date":"2025-10-03","current":-4.527069,"twenty":-1.745638,"median":-0.575974,"eighty":-0.433067,"marketCap":8995287},{"date":"2025-10-10","current":-4.350435,"twenty":-1.830305,"median":-0.578946,"eighty":-0.433701,"marketCap":8644315},{"date":"2025-10-17","current":-3.414928,"twenty":-1.87461,"median":-0.587012,"eighty":-0.433701,"marketCap":6785462},{"date":"2025-10-24","current":-2.878483,"twenty":-1.918497,"median":-0.592944,"eighty":-0.434682,"marketCap":5719546},{"date":"2025-10-31","current":-3.899037,"twenty":-1.958205,"median":-0.596003,"eighty":-0.436887,"marketCap":7747386},{"date":"2025-11-07","current":-2.865399,"twenty":-2.01879,"median":-0.600199,"eighty":-0.437769,"marketCap":5693548},{"date":"2025-11-14","current":-2.814442,"twenty":-2.071058,"median":-0.601951,"eighty":-0.439435,"marketCap":5581038},{"date":"2025-11-21","current":-2.853897,"twenty":-2.297704,"median":-0.603709,"eighty":-0.440807,"marketCap":5659277},{"date":"2025-11-28","current":-2.945958,"twenty":-2.315871,"median":-0.605099,"eighty":-0.441052,"marketCap":5841834},{"date":"2025-12-05","current":-3.011716,"twenty":-2.360357,"median":-0.610146,"eighty":-0.441052,"marketCap":5972232},{"date":"2025-12-12","current":-2.972261,"twenty":-2.438233,"median":-0.617439,"eighty":-0.441052,"marketCap":5893994},{"date":"2025-12-19","current":-2.538258,"twenty":-2.548779,"median":-0.623646,"eighty":-0.441331,"marketCap":5033366},{"date":"2025-12-26","current":-2.735532,"twenty":-2.604016,"median":-0.629412,"eighty":-0.441772,"marketCap":5424560},{"date":"2026-01-02","current":-2.380439,"twenty":-2.604016,"median":-0.639463,"eighty":-0.442179,"marketCap":4720411},{"date":"2026-01-09","current":-2.735532,"twenty":-2.63781,"median":-0.658368,"eighty":-0.442375,"marketCap":5424560},{"date":"2026-01-16","current":-2.643603,"twenty":-2.643471,"median":-0.661843,"eighty":-0.442792,"marketCap":5242264},{"date":"2026-01-23","current":-2.63032,"twenty":-2.643603,"median":-0.663639,"eighty":-0.44289,"marketCap":5215924},{"date":"2026-01-30","current":-2.235772,"twenty":-2.643471,"median":-0.664172,"eighty":-0.445953,"marketCap":4433535},{"date":"2026-02-06","current":-3.406264,"twenty":-2.709229,"median":-0.677388,"eighty":-0.449628,"marketCap":6754621},{"date":"2026-02-13","current":-4.059663,"twenty":-2.735532,"median":-0.67969,"eighty":-0.452079,"marketCap":4981207},{"date":"2026-02-19","current":-4.059663,"twenty":-2.740793,"median":-0.692832,"eighty":-0.452111,"marketCap":4981207}],"updateTime":1771586553689},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VIVS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610305909","title":"VivoSim Labs Unveils NAMkind Models Showing Strong Clinical Correlation for Antibody Drug Conjugate Toxicity","url":"https://stock-news.laohu8.com/highlight/detail?id=2610305909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610305909?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:05","pubTimestamp":1770815115,"startTime":"0","endTime":"0","summary":"VivoSim Labs Inc. has announced that it will present new data on its NAMkind liver and NAMkind Intestine models at the upcoming Society of Toxicology meeting in San Diego, scheduled for March 22-25. The company will showcase data validating these 3D human cell models for predicting toxicity and side effect profiles of antibody drug conjugates . According to VivoSim, testing of approved ADC therapies in the NAMkind models demonstrated a high correlation with clinical results, particularly regarding liver toxicity and intestinal side effects such as diarrhea. These results will be presented for the first time at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLZD94V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","SG9999014039.USD","VIVS","LU2210149790.SGD","NDAQ","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","IE00BKPKM429.USD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2607170770","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2607170770","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607170770?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:08","pubTimestamp":1769774938,"startTime":"0","endTime":"0","summary":"VivoSim Labs  shares were up 70% in recent Friday premarket activity, a day after the pharmaceutical and biotechnology services company signed agreements designating JCBio as its distributor in South Korea and Tekon Biotech in China for its NAMKind toxicology services.Twin Hospitality  stock was up 72%, erasing Thursday's loss.Deckers Outdoor  stock was up 13%, a day after the company posted higher fiscal Q3 earnings and net sales, and raised its fiscal 2026 outlook.ResMed  shares were 4% higher after the company posted overnight higher fiscal Q2 adjusted earnings and revenue.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RMD.AU","LU0266013472.USD","BK7501","BK4585","IE00B5TLWC47.USD","RMD","TWNPQ","DECK","BK4082","BK4146","LU2008162690.USD","BK4548","BK4504","BK7007","BK4567","BK4139","LU0170899867.USD","LU2177674079.SGD","VIVS","BK4588","BK4209","TWNP"],"gpt_icon":0},{"id":"2607148056","title":"VivoSim Labs Signs Distribution Agreements with JCBio in Korea and Tekon Biotech in China for NAMKind Toxicology Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2607148056","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607148056?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:05","pubTimestamp":1769720744,"startTime":"0","endTime":"0","summary":"VivoSim Labs Inc. announced the appointment of JCBio as its authorized distributor in Korea and Tekon Biotech as its authorized distributor in China for its NAMKind toxicology services focused on liver and small intestine screening. These distribution agreements will provide pharmaceutical and biotechnology organizations in Korea and China with access to VivoSim's human-based New Approach Methodologies  for preclinical safety assessment. The company aims to offer decision-ready toxicology data with a targeted 30-day turnaround time per study, supporting faster and earlier de-risking of drug development pipelines in the Asia-Pacific region.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL76S07t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","VIVS","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD"],"gpt_icon":0},{"id":"2607564250","title":"Vivosim Expands Asia-Pacific Access to Namkind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China","url":"https://stock-news.laohu8.com/highlight/detail?id=2607564250","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607564250?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:05","pubTimestamp":1769720700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUABXH3TS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIVS","BK4139"],"gpt_icon":0},{"id":"2601188068","title":"BRIEF-Vivosim Labs Appoints Amar Sethi, M.D., Ph.D. As Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601188068","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601188068?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:53","pubTimestamp":1767707614,"startTime":"0","endTime":"0","summary":"BRIEF-Vivosim Labs Appoints Amar Sethi, M.D., Ph.D. As Chief Scientific OfficerJan 6 (Reuters) - VivoSim Labs Inc VIVS.O:VIVOSIM LABS APPOINTS AMAR SETHI, M.D., PH.D. AS CHIEF SCIENTIFIC OFFICERSource text: ID:nGNX3KxnL3Further company coverage: VIVS.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA9T4SFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIVS"],"gpt_icon":0},{"id":"2601971958","title":"VivoSim Labs Names Amar Sethi Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601971958","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601971958?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:05","pubTimestamp":1767704713,"startTime":"0","endTime":"0","summary":"VivoSim Labs Inc. has appointed Amar Sethi, M.D., Ph.D., as its new Chief Scientific Officer. Dr. Sethi will lead the company’s scientific strategy across toxicology, translational models, bioanalytics, and new approach methodologies, and will work closely with R&D and AI teams to enhance toxicity prediction using human-relevant systems.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL10WqKd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","VIVS","BK4139","BK4112"],"gpt_icon":0},{"id":"2601897931","title":"Vivosim Labs Appoints Amar Sethi, M.d., Ph.d. as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897931","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897931?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:05","pubTimestamp":1767704700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA9T4SFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIVS","BK4139"],"gpt_icon":0},{"id":"2601897929","title":"Press Release: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897929","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601897929?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:05","pubTimestamp":1767704700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 06, 2026  -- VivoSim Labs, Inc.  , a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional  human tissue models of liver and intestine, announces it has appointed Amar Sethi, M.D., Ph.D. as its Chief Scientific Officer.Dr. Sethi is a transformational R&D executive with three decades of experience encompassing pharmaceutical drug development, CRO leadership, translational medicine, and diagnostic innovation. He has led global Phase I--IV clinical programs, FDA breakthrough and orphan drug designations, BLA filings, and advanced biomarker strategies across metabolic disorders, nephrology, hematology, rare diseases, and cardiovascular biology. His expertise includes establishing CAP/CLIA/GCP/GLP-compliant infrastructures, scaling bioanalytical and biomarker teams, and guiding scientific strategy for both early and late-stage assets.\"Amar brings an exceptional combination of scientific depth,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIVS","BK4139"],"gpt_icon":0},{"id":"2592819271","title":"VivoSim Labs Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592819271","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592819271?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:06","pubTimestamp":1766092008,"startTime":"0","endTime":"0","summary":"VivoSim Labs Inc. held its Annual Meeting of Stockholders on December 16, 2025. Stockholders elected Douglas Jay Cohen and David Gobel to the board of directors. The appointment of Rosenberg Rich Baker Berman P.A. as independent auditors was ratified. Stockholders also approved holding future advisory votes on executive compensation on an annual basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLS1mBx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIVS","BK4139"],"gpt_icon":0},{"id":"2586957782","title":"VivoSim Labs Inc. Files Initial Statement of Beneficial Ownership for Chief Scientific Officer Amar Akhtar Sethi","url":"https://stock-news.laohu8.com/highlight/detail?id=2586957782","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586957782?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:08","pubTimestamp":1764198505,"startTime":"0","endTime":"0","summary":"VivoSim Labs Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing identifies Amar Akhtar Sethi as the beneficial owner, serving in the role of Chief Scientific Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLbpGWpd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VIVS"],"gpt_icon":0},{"id":"2561817448","title":"VivoSim Labs Inc. Files Initial Beneficial Ownership Statement for Chief Commercial Officer Tony Serge Lialin","url":"https://stock-news.laohu8.com/highlight/detail?id=2561817448","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561817448?lang=en_us&edition=fundamental","pubTime":"2025-08-22 08:41","pubTimestamp":1755823296,"startTime":"0","endTime":"0","summary":"VivoSim Labs Inc. has filed an initial statement of beneficial ownership. The filing lists Tony Serge Lialin as the beneficial owner, who serves as the Chief Commercial Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250822:nNDL5ZsScz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIVS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}